OpenAI researcher Miles Wang is in advanced talks to launch an AI-focused drug discovery startup that would command a $2 billion valuation in its funding round, according to sources familiar with the matter. The company would apply large language models and machine learning to accelerate pharmaceutical development, targeting a space where AI has shown measurable promise in identifying drug candidates and predicting molecular behavior.
Wang's move reflects a broader surge in venture capital appetite for AI applied to life sciences. Investors view drug discovery as one of the highest-ROI applications for machine learning, given the sector's massive R&D budgets and lengthy development timelines that AI could compress. Companies like Recursion Pharmaceuticals, Exscientia, and Atomwise have already attracted significant funding by positioning AI as a tool to reduce both the time and cost of bringing new drugs to market.
The $2 billion valuation signals investor confidence in Wang's execution and OpenAI's research credibility. Wang's departure from OpenAI, where he contributed to the company's AI research, lends technical credibility to the venture. Life sciences investors view former researchers from leading AI labs as de facto proof points of scientific rigor.
The startup enters a crowded but expanding market. Recursion raised $200 million in 2022 at a $5 billion valuation. Exscientia went public in 2021 and has since faced valuation pressure. Despite these headwinds, the sector continues attracting capital because pharma companies remain willing to partner with AI startups to reduce discovery costs. A typical drug costs $2.6 billion and takes 10 years to develop. Any tooling that shaves years or hundreds of millions off that timeline commands buyer attention.
Wang's startup would likely focus on target identification or compound screening, where AI models excel at parsing vast biological datasets. The timing matters. OpenAI